Immunotherapy biotech CatalYm has appointed four seasoned industry executives, including Sujata Rao as Chief Medical Officer and Clinton Musil as Chief Business and Financial Officer, while three senior leaders, including Chief Scientific Officer Christine Schuberth-Wagner, departed. These changes aim to expedite late-stage clinical development of visugromab, a monoclonal antibody targeting GDF-15 for solid tumors and cachexia. The new leadership enhances representation from global biopharma expertise and underscores CatalYm's commitment to advancing novel cancer therapies.